Mission Bio and German Research Consortium Identify Single-Cell Biomarker Signal That May Predict Motixafortide Benefit in AML
Mission Bio, a leader in single-cell multiomics, has jointly announced new findings with Heidelberg University Hospital, Martin Luther University Halle-Wittenberg, the East German Study Group for Hematology and Oncology (OSHO), and the Study Alliance Leukemia (SAL). The results come from a retrospective single-cell analysis of the randomized Phase II BLAST clinical trial in acute myeloid leukemia (AML), offering new insights into how clonal biomarker profiling may help identify patients most likely to benefit from targeted therapy.
The BLAST study, an investigator-initiated, randomized, double-blind, placebo-controlled Phase II trial, evaluated whether adding the CXCR4 inhibitor motixafortide to high-dose cytarabine consolidation therapy could improve relapse-free survival in AML patients in first complete remission. Although the overall trial did not meet its primary endpoint, the newly reported single-cell analysis suggests that a biologically defined subgroup of patients may derive meaningful benefit from the treatment.
A Large Multicenter Clinical Effort in AML
The BLAST trial enrolled 128 patients across 29 academic centers in Germany. The study was sponsored by Martin Luther University Halle-Wittenberg, scientifically coordinated and led by Heidelberg University Hospital, and conducted with active participation from OSHO and SAL, two major cooperative oncology groups in the region.
Patients were randomized to receive either motixafortide plus high-dose cytarabine consolidation or placebo plus high-dose cytarabine following achievement of first complete remission. The primary endpoint was relapse-free survival (RFS), a critical measure in AML where disease recurrence remains a major clinical challenge even after initial remission.
Across the full study population, results showed no significant difference between the treatment arms. Median relapse-free survival was 10.3 months in the motixafortide group compared with 11.5 months in the placebo group, with no statistical significance observed (log-rank p = 0.98). These findings initially indicated that the addition of CXCR4 inhibition did not improve outcomes for the overall unselected patient population.
However, the availability of stored bone marrow samples enabled a deeper retrospective analysis using advanced single-cell technologies, revealing potentially important biological heterogeneity that was not captured in the original clinical endpoints.
Single-Cell Multiomics Reveals Hidden Biological Subgroups
The retrospective analysis was performed using Mission Bio’s Tapestri platform, which enables simultaneous single-cell DNA and protein profiling. This technology allowed researchers to examine CXCR4 expression specifically on genetically defined leukemic cells rather than on bulk bone marrow populations, a key distinction in a disease characterized by extreme cellular and clonal complexity.
In post-consolidation AML, residual leukemic cells are often extremely rare and embedded within a background of predominantly normal hematopoietic cells. Traditional bulk sequencing or flow cytometry approaches can struggle to distinguish whether biomarker signals originate from malignant clones or normal cells. The Tapestri platform addressed this limitation by linking protein expression directly to individual leukemic genotypes at single-cell resolution.
This approach enabled researchers to reconstruct clonal architecture and track how CXCR4 expression varied across distinct subclones during and after treatment. The results demonstrated that different leukemic subpopulations within the same patient could show markedly different CXCR4 dynamics over time, underscoring the complexity of residual disease biology.
CXCR4 Expression Linked to Opposing Clinical Outcomes
A key finding from the analysis was the role of CXCR4 expression on residual leukemic cells in predicting treatment response.
Among patients who received motixafortide, high CXCR4 expression on residual leukemic cells was associated with a significantly reduced risk of relapse (p = 0.047). In contrast, in the placebo group, high CXCR4 expression was associated with a significantly increased risk of relapse (p = 0.02). These opposing effects are consistent with the known biological role of the CXCR4–CXCL12 signaling axis in promoting leukemic cell retention and chemoresistance within the bone marrow microenvironment.
A multivariable Cox proportional hazards model further confirmed a strong treatment-by-biomarker interaction, with a statistically significant interaction term (p = 0.0015). This suggests that CXCR4 expression is not only prognostic but may also be predictive of response to CXCR4 inhibition.
From Negative Trial to Biomarker-Defined Opportunity
Although the BLAST trial was negative in its primary endpoint analysis, the single-cell results highlight how population-level outcomes can obscure meaningful therapeutic effects in genetically and phenotypically heterogeneous diseases like AML.
The findings suggest that motixafortide may be particularly effective in patients whose residual leukemic cells express high levels of CXCR4, a subgroup that may have been diluted in the overall trial population. This supports the hypothesis that CXCR4 inhibition could have clinically meaningful benefit when applied in a biomarker-selected population.
Importantly, researchers emphasized that these results are retrospective and hypothesis-generating, and therefore cannot yet be used to guide clinical decision-making. Prospective validation in biomarker-stratified clinical trials will be required before CXCR4 expression on residual leukemic cells can be incorporated into routine AML treatment algorithms.
Importance of Single-Cell MRD Profiling in AML
The study highlights a broader shift in leukemia research toward single-cell measurable residual disease (MRD) profiling, which allows researchers to study rare cancer cells with far greater resolution than traditional methods.
By linking genetic identity with protein expression at the single-cell level, researchers were able to capture functional heterogeneity within minimal residual disease—a critical driver of relapse in AML. This approach provides a more precise understanding of how individual leukemic clones respond to therapy and evolve under treatment pressure.
According to the study team, integrating single-cell MRD profiling into clinical trial design could improve the ability to identify patients who are most likely to benefit from targeted therapies and help refine treatment strategies in high-risk AML populations.
Expert Perspectives on the Findings
Dr. Enise Ceran, MD, first author of the study from the Medical Department V at Heidelberg University Hospital, emphasized that the biological meaning of a biomarker can vary significantly depending on treatment context.
She noted that while high CXCR4 expression identifies patients at increased risk of relapse, it also appears to mark those most likely to benefit from CXCR4-targeted therapy. However, she stressed that accurately identifying these patients requires measuring CXCR4 directly on residual leukemic cells and linking it to clonal identity, which is only possible through single-cell approaches.
Professor Carsten Müller-Tidow, MD, corresponding author and a leading hematology and oncology expert at Heidelberg University Hospital, highlighted the importance of functional characterization of residual disease. He emphasized that AML is not a uniform condition but a dynamic system of evolving clones, requiring advanced tools to understand its biology and guide therapy selection.
From an industry perspective, Mission Bio’s Chief Medical Officer, Dr. Zivjena Vucetic, described AML as a highly complex, evolving disease ecosystem. She noted that the study demonstrates the importance of matching the right drug to the right patient population and highlighted the role of single-cell multiomics in enabling this precision approach.
Implications for Future AML Clinical Trial Design
Mission Bio and its academic collaborators emphasized that AML’s clonal heterogeneity presents a major challenge for traditional biomarker strategies, which often rely on averaged signals from bulk tumor populations. These methods can mask clinically relevant subclonal differences that influence treatment response and disease progression.
The company stated that it is actively working with clinical partners to incorporate Tapestri-based biomarker screening into prospective clinical trial designs. This approach could enable more precise patient stratification and improve the likelihood of demonstrating therapeutic benefit in genetically defined subgroups.
Toward Precision Medicine in Acute Myeloid Leukemia
The findings from the BLAST trial analysis underscore a broader evolution in oncology toward precision medicine strategies that integrate genomic and functional data at single-cell resolution.
While the overall trial did not demonstrate benefit in an unselected AML population, the identification of a CXCR4-high subgroup responsive to motixafortide suggests a potential path forward for biomarker-driven therapy development.
If validated prospectively, these results could help redefine how CXCR4-targeted therapies are deployed in AML and reinforce the role of single-cell multiomics in uncovering clinically actionable insights hidden within complex cancer ecosystems.
The study ultimately highlights both the challenges and opportunities in treating AML—where disease heterogeneity has historically limited therapeutic success, but where emerging technologies are beginning to reveal new avenues for precision-guided treatment strategies.
About Mission Bio
Mission Bio is the single-cell multi-omics leader. The company’s Tapestri Platform is unique in its capabilities, offering an unparalleled level of granularity and precision that is critical for complex research areas such as cancer studies, pharmaceutical development, and advanced cell and gene therapies. Unlike traditional standard of care methods, Tapestri provides a level of precision that opens the door for more tailored and effective treatment strategies, notably by advancing the clinical utility of measurable residual disease (MRD) monitoring in diseases like acute myeloid leukemia (AML).
Researchers globally depend on Tapestri to identify rare cell populations, understand mechanisms of therapeutic resistance and response, and establish key quality metrics for next-generation medical treatments. With the Tapestri Platform, Mission Bio continued to set the standard in the field, contributing significantly to the progress of personalized medicine and targeted therapies.
